about
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-βSubcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeysAnalysis of erlotinib and its metabolites in rat tissue sections by MALDI quadrupole time-of-flight mass spectrometry.Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.Mechanistic determinants of biotherapeutics absorption following SC administration.Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in MiceNon-clinical pharmacokinetic/pharmacodynamic and early clinical studies supporting development of a novel subcutaneous formulation for the monoclonal antibody rituximab.The effects of interleukin-6 signal blockade on immune system, reproductive and skeletal development in juvenile mice.Reproductive and developmental toxicology studies with gantenerumab in PS2APP transgenic mice.Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.Subcutaneous absorption of biotherapeutics: knowns and unknowns.New challenges and opportunities in nonclinical safety testing of biologics.Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis.The distribution pattern of radioactivity across different tissues in quantitative whole-body autoradiography (QWBA) studies.6-Alkoxy-5-aryl-3-pyridinecarboxamides, a new series of bioavailable cannabinoid receptor type 1 (CB1) antagonists including peripherally selective compounds.Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.In Vivo Biotransformation of the Fusion Protein Tetranectin-Apolipoprotein A1 Analyzed by Ligand-Binding Mass Spectrometry Combined with Quantitation by ELISA.Hematopoietic cells as site of first-pass catabolism after subcutaneous dosing and contributors to systemic clearance of a monoclonal antibody in mice.Animal pharmacokinetics and interspecies scaling of Ro 25-6833 and related (lactamylvinyl)cephalosporinsPotential errors in the volume of distribution estimation of therapeutic proteins composed of differently cleared componentsImmunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion ProteinCD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic MalignanciesSubcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and OpportunitiesHigh-Throughput, Sensitive LC-MS Quantification of Biotherapeutics and Biomarkers Using Antibody-Free, Peptide-Level, Multiple-Mechanism Enrichment via Strategic Regulation of pH and Ionic and Solvent StrengthsAre Biotransformation Studies of Therapeutic Proteins Needed? Scientific Considerations and Technical ChallengesDesign of experiment (DOE) methods maximize information from a minimal number of animals in special cases of preclinical bioavailability testing
P50
Q27674567-8C22B6A8-970C-4A5F-9A75-BE158FEC6DBAQ28535043-941405E4-F960-4D60-8E28-A7AAD8459DF1Q33286050-C0CA04E0-E5F6-4595-A159-E9A124C53199Q35992509-9B5F2FBF-AD19-4D7A-834D-DAC4A925B914Q36065572-9C39D0BC-7FB4-4377-BB09-47912CED05FDQ36653919-B2479D9E-8658-4848-9074-1BAA50022100Q38180978-38AC154D-DBD4-48E8-B2ED-FE6CA091E78FQ45189804-45460EA6-6290-46C6-A285-EB893870180AQ46329142-31F36A4C-C444-44E5-A688-1674D071162EQ46495190-5BDD3F6F-2CCC-46C4-80A9-D6928FDD4270Q46855725-4ED99660-3D9E-46FA-85A5-B26336EBBE0CQ46902769-08AEB6A7-1503-4CDD-B5F8-12E18AEB811DQ47792039-0B830197-B279-4934-BC7C-2237A2ED48A6Q48631954-1C94C976-9FDE-4DD5-9A6E-78FD66F7A188Q48903567-F0EA2A7A-E9F9-4617-A808-B6840AA2C424Q49885070-0E0FA401-E8D4-46AF-B136-AC85B0E7DCD6Q51277326-82E0C93A-76C3-4D82-96DD-4881A0F6123DQ52604519-9F432E27-89BA-4539-8C3C-FABA7B24F13DQ74457426-9FBFB95E-BB96-40E2-8F44-E2B270D9C01CQ84584275-1F2F0A05-EAFF-4C87-8ED1-A8398BEDB683Q87106641-02BE7054-CC9F-4985-83CB-2F541CE9625BQ88537033-92959908-A634-4071-83E8-0B7A3C442B71Q90457449-C0E42B72-B0E2-4B7D-A823-B7D802F39474Q91319894-832696CD-B266-42FA-AA6E-D0DAD498E09FQ91360727-0869176E-CC13-4367-A7EB-2F19201F0A4FQ94327459-8454E7B7-6319-4599-8F4D-6444BBE58A48
P50
description
researcher
@en
wetenschapper
@nl
name
Richter WF
@nl
Wolfgang F. Richter
@en
type
label
Richter WF
@nl
Wolfgang F. Richter
@en
altLabel
Richter WF
@en
prefLabel
Richter WF
@nl
Wolfgang F. Richter
@en
P106
P31
P496
0000-0002-8094-8605